276 related articles for article (PubMed ID: 22641352)
21. Selective interaction of a conformationally-constrained Arg-Gly-Asp (RGD) motif with the integrin receptor alphavbeta3 expressed on human tumor cells.
Lanza P; Felding-Habermann B; Ruggeri ZM; Zanetti M; Billetta R
Blood Cells Mol Dis; 1997 Aug; 23(2):230-41. PubMed ID: 9268674
[TBL] [Abstract][Full Text] [Related]
22. Proteomics analysis of a novel compound: cyclic RGD in breast carcinoma cell line MCF-7.
Juan HF; Wang IH; Huang TC; Li JJ; Chen ST; Huang HC
Proteomics; 2006 May; 6(10):2991-3000. PubMed ID: 16619296
[TBL] [Abstract][Full Text] [Related]
23. Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3.
Yu YP; Wang Q; Liu YC; Xie Y
Biomaterials; 2014 Feb; 35(5):1667-75. PubMed ID: 24268666
[TBL] [Abstract][Full Text] [Related]
24. Expression, purification, and characterization of RGD-mda-7, a His-tagged mda-7/IL-24 mutant protein.
Liu JJ; Zhang BF; Yin XX; Pei DS; Yang ZX; Di JH; Chen FF; Li HZ; Xu W; Wu YP; Zheng JN
J Immunoassay Immunochem; 2012; 33(4):352-68. PubMed ID: 22963485
[TBL] [Abstract][Full Text] [Related]
25. Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β₃ integrin ligands: An approach to tumor-targeted therapy.
Dal Pozzo A; Esposito E; Ni M; Muzi L; Pisano C; Bucci F; Vesci L; Castorina M; Penco S
Bioconjug Chem; 2010 Nov; 21(11):1956-67. PubMed ID: 20949910
[TBL] [Abstract][Full Text] [Related]
26. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
27. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin.
Choi Y; Kim E; Lee Y; Han MH; Kang IC
Proteomics; 2010 Jan; 10(1):72-80. PubMed ID: 19882657
[TBL] [Abstract][Full Text] [Related]
28. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide.
E M Eid E; S Alanazi A; Koosha S; A Alrasheedy A; Azam F; M Taban I; Khalilullah H; Sadiq Al-Qubaisi M; A Alshawsh M
Molecules; 2019 Jul; 24(14):. PubMed ID: 31337024
[TBL] [Abstract][Full Text] [Related]
29. Bicyclic RGD Peptides with Exquisite Selectivity for the Integrin α
Bernhagen D; Jungbluth V; Quilis NG; Dostalek J; White PB; Jalink K; Timmerman P
ACS Comb Sci; 2019 Mar; 21(3):198-206. PubMed ID: 30624885
[TBL] [Abstract][Full Text] [Related]
30. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering.
Guo Z; He B; Jin H; Zhang H; Dai W; Zhang L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2014 Jul; 35(23):6106-17. PubMed ID: 24794924
[TBL] [Abstract][Full Text] [Related]
31. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.
Beck V; Herold H; Benge A; Luber B; Hutzler P; Tschesche H; Kessler H; Schmitt M; Geppert HG; Reuning U
Int J Biochem Cell Biol; 2005 Mar; 37(3):590-603. PubMed ID: 15618016
[TBL] [Abstract][Full Text] [Related]
32. Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin.
Richards J; Miller M; Abend J; Koide A; Koide S; Dewhurst S
J Mol Biol; 2003 Mar; 326(5):1475-88. PubMed ID: 12595259
[TBL] [Abstract][Full Text] [Related]
33. Toward Angiogenesis Inhibitors Based on the Conjugation of Organometallic Platinum(II) Complexes to RGD Peptides.
Zamora A; Gandioso A; Massaguer A; Buenestado S; Calvis C; Hernández JL; Mitjans F; Rodríguez V; Ruiz J; Marchán V
ChemMedChem; 2018 Sep; 13(17):1755-1762. PubMed ID: 29932312
[TBL] [Abstract][Full Text] [Related]
34. Design and activity of multifunctional fibrils using receptor-specific small peptides.
Ohga Y; Katagiri F; Takeyama K; Hozumi K; Kikkawa Y; Nishi N; Nomizu M
Biomaterials; 2009 Dec; 30(35):6731-8. PubMed ID: 19765823
[TBL] [Abstract][Full Text] [Related]
35. Cyclic RGD and
Panzeri S; Arosio D; Gazzola S; Belvisi L; Civera M; Potenza D; Vasile F; Kemker I; Ertl T; Sewald N; Reiser O; Piarulli U
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339382
[TBL] [Abstract][Full Text] [Related]
36. Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.
Del Gatto A; Zaccaro L; Grieco P; Novellino E; Zannetti A; Del Vecchio S; Iommelli F; Salvatore M; Pedone C; Saviano M
J Med Chem; 2006 Jun; 49(11):3416-20. PubMed ID: 16722662
[TBL] [Abstract][Full Text] [Related]
37. alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers.
Rerat V; Dive G; Cordi AA; Tucker GC; Bareille R; Amédée J; Bordenave L; Marchand-Brynaert J
J Med Chem; 2009 Nov; 52(22):7029-43. PubMed ID: 19860432
[TBL] [Abstract][Full Text] [Related]
38. Molecular modeling of the thyroid hormone interactions with alpha v beta 3 integrin.
Cody V; Davis PJ; Davis FB
Steroids; 2007 Feb; 72(2):165-70. PubMed ID: 17166537
[TBL] [Abstract][Full Text] [Related]
39. Melanoma cell surface-expressed phosphatidylserine as a therapeutic target for cationic anticancer peptide, temporin-1CEa.
Wang C; Chen YW; Zhang L; Gong XG; Zhou Y; Shang DJ
J Drug Target; 2016; 24(6):548-56. PubMed ID: 26596643
[TBL] [Abstract][Full Text] [Related]
40. R-isomers of Arg-Gly-Asp (RGD) mimics as potent alphavbeta3 inhibitors.
Nagarajan SR; Devadas B; Malecha JW; Lu HF; Ruminski PG; Rico JG; Rogers TE; Marrufo LD; Collins JT; Kleine HP; Lantz MK; Zhu J; Green NF; Russell MA; Landis BH; Miller LM; Meyer DM; Duffin TD; Engleman VW; Finn MB; Freeman SK; Griggs DW; Williams ML; Nickols MA; Pegg JA; Shannon KE; Steininger C; Westlin MM; Nickols GA; Keene JL
Bioorg Med Chem; 2007 Jun; 15(11):3783-800. PubMed ID: 17399986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
